CD4+ T cells are a major helper T-cell population and, in this entry, serve primarily as a source cell population for engineering, including generation of engineered regulatory T cells. They are also used as an activated T-cell model to study immunometabolic reprogramming, where arginine-loaded MOF-808 and NH2-MIL-125 altered metabolism and, for MOF-808-Arg, increased oxidative phosphorylation and spare respiratory capacity in mof 808– and nh2 mil 125-treated activated CD4+ T cells. In disease contexts, a CD4+ T-cell subset containing NMB+ CXCL13+ cells has been implicated in promoting malignant cell senescence and metastasis through neuromedin-B signaling. Overall, the literature here links CD4+ T cells to cell therapy engineering, metabolic modulation, and tumor immunology, with specific relevance to autoimmune disease and triple-negative breast cancer. The key facts emphasize their role as a source cell population for engineering, consistent with their use in preclinical regulatory T-cell manufacturing. Recent studies include a 2026 Molecular Therapy preclinical assessment of engineered regulatory T cells for IPEX and other autoimmune disorders (PMID:41832599), a 2026 Biomaterials Science study on arginine nanocarriers in activated CD4+ T cells (PMID:42029068), and a 2026 Cancer Immunology Research paper on NMB+ CXCL13+ CD4+ T cells (PMID:42029557).
Autoimmune disease / Cell therapy engineering
- CD4+ T cells were the starting cell population for generation of engineered regulatory T cells in a preclinical study of IPEX and other autoimmune disorders. (PMID:41832599)
- Engineered regulatory T cells were evaluated for preclinical efficacy and safety, highlighting CD4+ T cells as a manufacturing source for cell therapy. (PMID:41832599)
Immunometabolism / Delivery
- Activated CD4+ T cells were used to assess arginine-loaded MOF effects on metabolic reprogramming. (PMID:42029068)
- mof 808-Arg enhanced oxidative phosphorylation and spare respiratory capacity in activated CD4+ T cells. (PMID:42029068)
- nh2 mil 125-Arg altered the metabolic state of activated CD4+ T cells, supporting MOF-based immunometabolic modulation. (PMID:42029068)
Cancer
- A CD4+ T-cell subset containing NMB+ CXCL13+ cells was implicated in promoting malignant cell senescence and metastasis. (PMID:42029557)
- NMB+ CXCL13+ CD4+ T cells were linked to neuromedin-B signaling in malignant cells expressing neuropeptide S receptor 1. (PMID:42029557)
- The study connects CD4+ T-cell heterogeneity to tumor progression in cancer immunology. (PMID:42029557)